Disc Medicine IRON Accrued External Research And Development Expenses Current
Accrued External Research And Development Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept iron:AccruedExternalResearchAndDevelopmentExpensesCurrent.
The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Disc Medicine's accrued external research and development expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Disc Medicine's accrued external research and development expenses current?
- Disc Medicine (IRON) reported accrued external research and development expenses current of $12.14M in Q1 2026.
- How has Disc Medicine's accrued external research and development expenses current changed year-over-year?
- Disc Medicine's accrued external research and development expenses current increased by 63.5% year-over-year, from $7.42M to $12.14M.
- What is the long-term trend for Disc Medicine's accrued external research and development expenses current?
- Over 2 years (2023 to 2025), Disc Medicine's accrued external research and development expenses current has grown at a 140.1% compound annual growth rate (CAGR), from $1.99M to $11.45M.
- What does accrued external research and development expenses current mean?
- This metric represents the total amount of liabilities incurred for research and development activities performed by third-party vendors, such as contract research organizations or clinical trial sites, that have not yet been invoiced or paid. It reflects the company's short-term financial obligations for ongoing clinical studies and preclinical development programs. Monitoring this balance provides insight into the company's near-term cash requirements for its drug development pipeline.